Social value of statins merits actions to broaden treatment, improve adherence, study finds
News
Article
New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs.
Social value of statins merits actions to broaden treatment, improve adherence, study finds
New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs.
FDA Approves Attruby for Hearth Failure Indication
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a list price of $18,759 for a month’s supply.
Read More
CVS Caremark Makes Changes in Diabetes Coverage for 2025
CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
FDA Approves Biliary Tract Cancer Antibody Treatment
Produced in Chinese hamster ovary cells, Ziihera (zanidatamab-hrii) is the first HER2-targeted bispecific antibody treatment for patients with previously treated, unresectable or metastatic biliary tract cancer.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
FDA Approves Bimzelx for Inflammatory Skin Disease
The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this painful autoimmune skin disease.
Read More
Endo Recalls 16 Lots of Clonazepam Due to Mislabeling
A total of 17 lots are now part of the recall of Clonazepam because some cartons have the wrong strength on the label.
Read More
FDA Approves Attruby for Hearth Failure Indication
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a list price of $18,759 for a month’s supply.
Read More
CVS Caremark Makes Changes in Diabetes Coverage for 2025
CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
FDA Approves Biliary Tract Cancer Antibody Treatment
Produced in Chinese hamster ovary cells, Ziihera (zanidatamab-hrii) is the first HER2-targeted bispecific antibody treatment for patients with previously treated, unresectable or metastatic biliary tract cancer.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
FDA Approves Bimzelx for Inflammatory Skin Disease
The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this painful autoimmune skin disease.
Read More
Endo Recalls 16 Lots of Clonazepam Due to Mislabeling
A total of 17 lots are now part of the recall of Clonazepam because some cartons have the wrong strength on the label.
Read More